Synendos Therapeutics AG

About

Synendos Therapeutics AG is a Swiss clinical-stage neuroscience company focused on developing innovative and potentially breakthrough therapies for neuropsychiatric and CNS disorders. Utilizing over a decade of research from the University of Bern, the company develops first-in-class selective endocannabinoid reuptake inhibitors (SERIs), targeting a novel mechanism in the endocannabinoid system (ECS) to restore natural brain function. The lead candidate, SYT-510, is aimed at treating diseases with high unmet medical need such as post-traumatic stress disorder (PTSD). Synendos' approach is supported by strong preclinical and clinical evidence, a robust patent portfolio, and significant grant and venture capital funding.